The Unexpected Origin of a Modern Medical Marvel
John Eng, an endocrinologist based in the Bronx and working at the Veterans Affairs Medical Center, embarked on a challenging quest that would transform diabetes and weight management treatment worldwide. For years, Eng searched for a hormone capable of stabilizing blood sugar without causing dangerous crashes. His breakthrough came from an unlikely source: the venom of the Gila monster, a rare desert lizard known for eating only a few times annually.
Using dried venom samples sourced from Utah, Eng isolated a peptide in 1992 that mimicked the action of the human gut hormone GLP-1 (glucagon-like peptide-1) but with significantly greater stability. While the human version of GLP-1 breaks down within minutes in the bloodstream, the lizard’s peptide—called exendin-4—remained active for hours. This evolutionary adaptation allows the Gila monster to maximize the energy from its infrequent meals.
Despite this promising discovery, the Veterans Affairs (VA) Medical Center where Eng worked declined to file a patent. Undeterred, Eng patented the compound himself and licensed it to a small biotechnology company. This led to the development of the first commercial drug in this class, exenatide, which debuted as Byetta in 2005. Today, this molecule is the ancestor of a family of drugs—including Ozempic, Wegovy, Mounjaro, and Zepbound—that more than one in ten American adults now take for diabetes and weight loss (source).
The Science Behind GLP-1 and Its Pharmaceutical Evolution
Understanding GLP-1
GLP-1 is a hormone naturally released by the human gut after eating. It signals the pancreas to produce insulin and tells the brain to reduce appetite. However, the natural hormone degrades rapidly in the bloodstream—within about two minutes—rendering it ineffective as a drug. The Gila monster’s exendin-4 peptide, by contrast, persists for hours, an evolutionary trait supporting the lizard’s rare feeding pattern.
From Byetta to Breakthroughs
Byetta, launched by Amylin Pharmaceuticals in 2005, required twice-daily injections and was costly for patients. Yet it opened the door for further innovation. Novo Nordisk, a Danish pharmaceutical company with extensive experience in insulin therapies, developed longer-acting GLP-1 analogues such as liraglutide (Victoza for diabetes in 2010 and Saxenda for weight loss in 2014) and semaglutide (Ozempic, approved in 2017).
Semaglutide’s once-weekly injection was a game-changer. By chemically attaching a fatty acid chain, chemists enabled the molecule to bind to albumin in the blood, protecting it from enzymatic breakdown. The result: sustained activity over seven days and significant weight loss—up to 15% of body mass over a year, comparable to bariatric surgery outcomes.
Further advances include Wegovy (a higher-dose semaglutide for weight loss, FDA-approved in 2021) and Eli Lilly’s tirzepatide, marketed as Mounjaro (2022) and Zepbound (2023). Tirzepatide targets both GLP-1 and GIP receptors, producing average weight loss exceeding 20% in clinical trials.
The Rapid Rise of GLP-1 Drugs in America
The use of GLP-1 receptor agonists has exploded in the United States. In 2019, only a small fraction of diabetic patients used these medications. By 2023, influenced by viral social media trends, celebrity endorsements, and off-label use for weight loss, demand soared so quickly that Novo Nordisk warned of global shortages.
During the shortage, compounding pharmacies supplied grey-market alternatives, and telehealth companies capitalized on the trend by prescribing these drugs remotely. By mid-2026, surveys estimated that roughly one in eight American adults used GLP-1 drugs, with higher usage among women, older adults, and those with obesity (Forbes Health).
The Medicare GLP-1 Bridge: Expanding Access
Historically, Medicare was barred from covering weight-loss medications due to concerns rooted in the appetite-suppressant controversies of the early 2000s. This changed in 2026 when the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge pilot program. Starting July 1, 2026, eligible Medicare Part D beneficiaries could access GLP-1 drugs for a flat $50 monthly copay (NPR coverage).
The pilot runs through the end of 2027 and covers brand-name drugs like Wegovy and Zepbound, marking a dramatic reduction from prior list prices exceeding $1,300 per month. This pricing shift aligns with policy changes stemming from the Trump administration’s Most-Favored-Nation drug pricing framework, which aims to lower U.S. pharmaceutical prices by benchmarking against other developed countries. A White House analysis highlighted GLP-1 drugs as a leading example of cost savings under this policy (White House report).
The Employer Backlash and Economic Realities
While Medicare has begun easing access, many commercial insurers and employers are pulling back. After expanding GLP-1 coverage in 2022 and 2023, employers have seen pharmacy spending on these drugs double or triple, prompting many to restrict coverage primarily to diabetes or impose stringent prior authorizations for weight-loss indications.
According to Forbes contributor Bruce Japsen, a growing number of health plans are limiting benefits for these medications due to budget pressures (Forbes report). For self-funded employers, the math is stark: a workforce of 10,000 with 12% GLP-1 uptake at a discounted $500 monthly cost translates to approximately $7.2 million in annual drug expenses from this category alone.
How GLP-1 Drugs Work Inside the Body
GLP-1 receptor agonists act through multiple mechanisms to regulate appetite and glucose metabolism:
- They slow gastric emptying, prolonging the feeling of fullness after meals.
- They influence the hypothalamus and brain reward circuits, reducing cravings and “food noise.”
- They stimulate insulin secretion in a glucose-dependent manner, lowering blood sugar without typically causing hypoglycemia.
Side effects often reflect these mechanisms. Common early reactions include nausea, vomiting, and constipation. Though rare, serious risks such as pancreatitis, gallbladder disease, and thyroid C-cell tumors (observed in rodent studies) necessitate caution, particularly for patients with a family history of medullary thyroid cancer. Ongoing research explores broader benefits, including cardiovascular event reduction, slower chronic kidney disease progression, and potential impacts on Alzheimer’s and addiction.
The Untold Story Behind the Numbers
The widespread adoption of GLP-1 drugs masks a fascinating and complex history. The hormone GLP-1 itself was identified in the 1980s by researchers like Jens Juul Holst in Copenhagen and Daniel Drucker in Toronto, who studied proglucagon-derived peptides. Early on, many experts dismissed GLP-1 as too fragile to be therapeutically useful.
It took the perseverance of John Eng, a desert lizard’s unique biology, and the vision of a Danish pharmaceutical giant to transform GLP-1 into a stable, effective medication. Amylin Pharmaceuticals, which first commercialized Byetta, was acquired by Bristol-Myers Squibb in 2012 for $5.3 billion—largely reflecting the value of Eng’s lizard-venom-derived discovery that the VA had initially overlooked.
The Broader Impact on Society and Industry
The ripple effects of GLP-1 drugs extend beyond medicine. When roughly 12% of a population changes its appetite and weight, shifts occur in unexpected sectors. Walmart executives noted smaller grocery basket sizes among GLP-1 users as early as 2023. Snack food companies have reformulated products, airlines have analyzed average passenger weights, and bariatric surgery rates have declined for the first time in two decades.
None of this was anticipated when John Eng filed a patent for a molecule derived from a creature that eats only three meals a year. Over the past three decades, this unique peptide from a slow-moving desert lizard has become the molecular foundation of the most widely prescribed weight-loss drugs in history, fundamentally reshaping American health and commerce.
For more detailed information, please visit Here.
